| Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. | |
| | |
MedLine Citation:
|
PMID: 15251115 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To evaluate the anti-inflammatory action of macrolide antibiotics, we examined whether macrolide antibiotics could induce apoptosis of activated lymphocytes. The proportion of apoptotic cells was augmented by clarithromycin (CLR) and azithromycin (AZM) compared with control. There was no significant difference in Fas and Fas-ligand expression between the control and macrolide-treated groups. CLR and AZM inhibited the expression of Bcl-xL compared with that of control. Our results suggest that CLR and AZM enhance apoptosis of activated lymphocytes by down-regulation of Bcl-xL. |
| | |
Authors:
|
Syunji Mizunoe; Jun-Ichi Kadota; Issei Tokimatsu; Kenji Kishi; Hiroyuki Nagai; Masaru Nasu |
Related Documents
:
|
8562965 - Fanconi anemia genes act to suppress a cross-linker-inducible p53-independent apoptosis... 9256475 - Precursor b cells for autoantibody production in genomically fas-intact autoimmune dise... 11220355 - Dissociation between fas expression and induction of apoptosis in human islets of lange... 10611305 - Activation of fas by fasl induces apoptosis by a mechanism that cannot be blocked by bc... 23578665 - Lipopolysaccharide blocks induction of unfolded protein response in human hepatoma cell... 18634875 - Uncovering mechanisms of bistability in biological systems. |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: International immunopharmacology Volume: 4 ISSN: 1567-5769 ISO Abbreviation: Int. Immunopharmacol. Publication Date: 2004 Sep |
Date Detail:
|
Created Date: 2004-07-14 Completed Date: 2005-02-16 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100965259 Medline TA: Int Immunopharmacol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1201-7 Citation Subset: IM |
Affiliation:
|
Division of Pathogenesis and Disease Control, Department of Infectious Diseases, Oita University Faculty of Medicine, 1-1 Hasama, Oita 879-5593, Japan. mizunoe@med.oita-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anti-Bacterial Agents / pharmacology* Antigen-Presenting Cells Antigens, CD28 / immunology Antigens, CD3 / immunology Antigens, CD95 / biosynthesis Apoptosis / drug effects* Azithromycin / pharmacology* Cells, Cultured Clarithromycin / pharmacology* Down-Regulation / drug effects, physiology Fas Ligand Protein Humans Lymphocyte Activation / drug effects Lymphocytes / drug effects*, immunology Membrane Glycoproteins / biosynthesis Proto-Oncogene Proteins c-bcl-2 / biosynthesis* Stimulation, Chemical bcl-2-Associated X Protein bcl-X Protein |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Antigens, CD28; 0/Antigens, CD3; 0/Antigens, CD95; 0/BCL2L1 protein, human; 0/FASLG protein, human; 0/Fas Ligand Protein; 0/Membrane Glycoproteins; 0/Proto-Oncogene Proteins c-bcl-2; 0/bcl-2-Associated X Protein; 0/bcl-X Protein; 81103-11-9/Clarithromycin; 83905-01-5/Azithromycin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lactoferrin works as a new LPS-binding protein in inflammatory activation of macrophages.
Next Document: Pharmacokinetics of fungal (1-3)-beta-D-glucans following intravenous administration in rats.